Teva Pharmaceutical Industries Limited (TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced that it will release its financial results for the fourth quarter and full year of 2024, along with its financial outlook for 2025, on January 29, 2025, at 7:00 a.m. ET. After the announcement, there will be a conference call and live webcast at 8:00 a.m. ET on the same day.

Wall Street is preparing for the Federal Reserve's interest rate announcement, which will be released at 2 p.m. ET, and Yahoo Finance will cover it live. Nvidia (NVDA) shares are expected to recover after the Dow (^DJI) fell into correction territory recently. Some popular stocks on Yahoo Finance right now include Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), and Nissan (NSANY), with several key guests scheduled to speak throughout the morning.

Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi SA (SNY) have successfully achieved their main goals in the Phase 2b RELIEVE UCCD study for patients with ulcerative colitis (UC) and Crohn's disease (CD).

Teva Pharmaceuticals and its partner Sanofi have revealed impressive results from clinical trials for their drug, duvakitug, aimed at treating ulcerative colitis and Crohn's disease, which are common types of inflammatory bowel disease. Following this news, Teva's stock jumped by 26.4% to $20.88, while Sanofi's shares increased by 6.7% to $48.

Teva Pharmaceutical (TEVA) reached its highest stock price of the year after announcing that its IBD treatment, developed with Sanofi (SNY), showed better remission rates in trials. George Tsilis examines how this progress could mark the beginning of a recovery for the company.

Teva Pharmaceutical's stock has recovered from its lowest points due to reduced debt, stabilized prices in generics, and new product releases, making it a good investment choice. The company's innovative branded medications and biosimilar products, such as AUSTEDO and future biosimilars like PROLIA and RANIVISIO, present significant growth potential. Teva's business has experienced cycles of ups and downs, but major patent expirations for biologics in the next few years suggest another period of growth is on the horizon.

Teva Pharmaceutical Industries announced on Thursday that it will hand over its generic drug business in Japan to JKI.

On December 5, 2024, Teva Pharmaceutical Industries Ltd. announced that it has made a deal with JKI, which is run by the J-Will fund. As part of this agreement, all shares of Teva Takeda Pharma Limited and its fully owned subsidiary, Teva Takeda Yakuhin Ltd., will be handed over to JKI.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) will hold its 7th Annual Evercore ISI HealthCONx Healthcare Conference Call on December 5, 2024, at 8:20 AM ET. The company will be represented by Richard Francis, the President and CEO, and Eric Hughes, the Executive Vice President of Global R&D and Chief Medical Officer. Umer Raffat from Evercore ISI expressed his enthusiasm for having Teva's management present.